The 2020 revision of the guidelines for the management of myeloproliferative neoplasms
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Sung-Yong | - |
dc.contributor.author | Bae, Sung Hwa | - |
dc.contributor.author | Bang, Soo-Mee | - |
dc.contributor.author | Eom, Ki-Seong | - |
dc.contributor.author | Hong, Junshik | - |
dc.contributor.author | Jang, Seongsoo | - |
dc.contributor.author | Jung, Chul Won | - |
dc.contributor.author | Kim, Hee-Jin | - |
dc.contributor.author | Kim, Ho Young | - |
dc.contributor.author | Kim, Min Kyoung | - |
dc.contributor.author | Kim, Soo-Jeong | - |
dc.contributor.author | Mun, Yeung-Chul | - |
dc.contributor.author | Nam, Seung-Hyun | - |
dc.contributor.author | Park, Jinny | - |
dc.contributor.author | Won, Jong-Ho | - |
dc.contributor.author | Choi, Chul Won | - |
dc.date.accessioned | 2021-08-30T05:11:02Z | - |
dc.date.available | 2021-08-30T05:11:02Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2021-01 | - |
dc.identifier.issn | 1226-3303 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/50640 | - |
dc.description.abstract | In 2016, the World Health Organization revised the diagnostic criteria for myeloproliferative neoplasms (MPNs) based on the discovery of disease-driving genetic aberrations and extensive analysis of the clinical characteristics of patients with MPNs. Recent studies have suggested that additional somatic mutations have a clinical impact on the prognosis of patients harboring these genetic abnormalities. Treatment strategies have also advanced with the introduction of JAK inhibitors, one of which has been approved for the treatment of patients with myelofibrosis and those with hydroxyurea-resistant or intolerant polycythemia vera. Recently developed drugs aim to elicit hematologic responses, as well as symptomatic and molecular responses, and the response criteria were refined accordingly. Based on these changes, we have revised the guidelines and present the diagnosis, treatment, and risk stratification of MPNs encountered in Korea. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN ASSOC INTERNAL MEDICINE | - |
dc.subject | INTERNATIONAL WORKING GROUP | - |
dc.subject | STEM-CELL TRANSPLANTATION | - |
dc.subject | HEALTH-ORGANIZATION CLASSIFICATION | - |
dc.subject | RISK ESSENTIAL THROMBOCYTHEMIA | - |
dc.subject | PROGNOSTIC SCORING SYSTEM | - |
dc.subject | TYROSINE KINASE JAK2 | - |
dc.subject | QUALITY-OF-LIFE | - |
dc.subject | POLYCYTHEMIA-VERA | - |
dc.subject | PRIMARY MYELOFIBROSIS | - |
dc.subject | AVAILABLE THERAPY | - |
dc.title | The 2020 revision of the guidelines for the management of myeloproliferative neoplasms | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Choi, Chul Won | - |
dc.identifier.doi | 10.3904/kjim.2020.319 | - |
dc.identifier.scopusid | 2-s2.0-85099166939 | - |
dc.identifier.wosid | 000605630300006 | - |
dc.identifier.bibliographicCitation | KOREAN JOURNAL OF INTERNAL MEDICINE, v.36, no.1, pp.45 - 62 | - |
dc.relation.isPartOf | KOREAN JOURNAL OF INTERNAL MEDICINE | - |
dc.citation.title | KOREAN JOURNAL OF INTERNAL MEDICINE | - |
dc.citation.volume | 36 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 45 | - |
dc.citation.endPage | 62 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.identifier.kciid | ART002660572 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.subject.keywordPlus | INTERNATIONAL WORKING GROUP | - |
dc.subject.keywordPlus | STEM-CELL TRANSPLANTATION | - |
dc.subject.keywordPlus | HEALTH-ORGANIZATION CLASSIFICATION | - |
dc.subject.keywordPlus | RISK ESSENTIAL THROMBOCYTHEMIA | - |
dc.subject.keywordPlus | PROGNOSTIC SCORING SYSTEM | - |
dc.subject.keywordPlus | TYROSINE KINASE JAK2 | - |
dc.subject.keywordPlus | QUALITY-OF-LIFE | - |
dc.subject.keywordPlus | POLYCYTHEMIA-VERA | - |
dc.subject.keywordPlus | PRIMARY MYELOFIBROSIS | - |
dc.subject.keywordPlus | AVAILABLE THERAPY | - |
dc.subject.keywordAuthor | Polycythemia vera | - |
dc.subject.keywordAuthor | Thrombocythemia, essential | - |
dc.subject.keywordAuthor | Primary myelofibrosis | - |
dc.subject.keywordAuthor | Practice guideline | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.